HepaLipa-Study: Observing the influence of an IL-17 inhibition on liver steatosis and inflammation.
Not Applicable
Recruiting
- Conditions
- K76.0K75.8Fatty (change of) liver, not elsewhere classifiedOther specified inflammatory liver diseases
- Registration Number
- DRKS00027573
- Lead Sponsor
- niversitätsklinikum Freiburg, Department Innere Medizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Patients with an existing indication for drug therapy of psoriasis, psoriatic arthritis or ankylosing spondylitis.
Exclusion Criteria
other liver diseases (ethyl toxic, viral, secondary), acutely life-threatening diseases, pregnant women, known drug abuse or participation in a drug substitution program, inability to give consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Observation of the immune response (Th17 / Treg ratio) and the course of NAFLD (Fib4 Score, NAFLD-Fibrosis Score, CK18, hyaluronic acid) under therapy with IL-17 antagonists.
- Secondary Outcome Measures
Name Time Method